The systematic name of Varenicline tartrate 7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline 2,3-dihydroxybutanedioate (1:1) . With the CAS registry number 375815-87-5, it is also named as 6,10-Methano-6H-pyrazino(2,3-h)(3)benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) ; CP 526555-18 ; Champix ; Chantix ; UNII-82269ASB48 .

The Varenicline tartrate is tan solid. It is a drug for the treatment of nicotine addiction which was developed by a pharmaceutical company in United States. In 2006, the drug is approved by U.S. Food and Drug Administration (FDA), which is the first new prescription smoking cessation drugs in the last 10 years. The most common side effects are including nausea, abnormal dreams, constipation, flatulence and vomiting.

The product is orally active, subtype-selective partial agonist at α 4 β 2 nicotinic receptors (K i values are 0.06, 240, 322 and 3540 nM for α 4 β 2, α 3 β 4, α 7, α 1 β γ δ receptors respectively). Reduces nicotine-evoked dopamine release in vitro and decreases nicotine self-administration in vivo .

The other characteristics of this product can be summarized as: (1)#H bond acceptors: 3 ; (2)#H bond donors: 1 ; (3)Enthalpy of Vaporization: 65.15 kJ/mol ; (4)Vapour Pressure: 1.25E-06 mmHg at 25°C ; (5)Rotatable Bond Count: 3 ; (6)Exact Mass: 361.127385 ; (7)MonoIsotopic Mass: 361.127385 ; (8)Topological Polar Surface Area: 153 ; (9)Heavy Atom Count: 26 ; (10)Complexity: 388.

People can use the following data to convert to the molecule structure. SMILES: O=C(O)[C@@H](O)[C@H](O)C(=O)O.n1c2cc3c(cc2ncc1)C4CNCC3C4; InChI: InChI=1/C13H13N3.C4H6O6/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1;5-1(3(7)8)2(6)4(9)10/h1-2,4-5,8-9,14H,3,6-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.0/s1.